SAUGUS, Mass., Oct. 04, 2018 (GLOBE NEWSWIRE) -- IonSense, Inc. has announced that in collaboration with Cayman Chemical, Inc. they have built and validated a mass spectral database of 1000 compounds for the rapid screening of drugs of abuse using Direct Analysis in Real Time (DART®) mass spectrometry analysis. There is an increasing need for the rapid and accurate detection of emerging drugs of abuse, and this database includes the latest fentanyl related compounds as well as opioids, cannabinoids, cathinones, benzodiazepenes, and various designer drugs.
The database is built using Certified Referenced Materials and analytical drug standards produced by Cayman Chemical. The compounds are analyzed with a DART-equipped Waters QDa® single-quadrupole mass spectrometer utilizing in-source fragmentation, a form of collision induced dissociation, to generate a collection of compound related ions allowing for more confident identification. The combination of the DART with the QDa is the result of the collaboration with Waters announced in June of this year.
“We are pleased to work with the experts at Cayman as we build this valuable resource,” according to Brian Musselman, IonSense President and CEO. “This new database coupled with DART technology can address the rapidly evolving challenge of identifying drugs of abuse.” The DART QDa and forensic database is currently implemented at the FDA Forensics Chemistry Center in Cincinnati, Ohio.
About IonSense Corporation (www.ionsense.com)
IonSense Inc., established in 2005, is the leading provider of Open Air/Ambient Ionization sources, systems and integrated solutions for the $4B Mass Spectrometry marketplace. Headquartered in Saugus, MA the company manufactures, sells and markets the DART® (Direct Analysis in Real Time) ionization source, the first open air ionization product to be patented and sold commercially. DART is a trademark of JEOL USA. QDa is a trademark of Waters Technologies Corporation.